In this regard, SGLT2 inhibitors were recently shown to have heart and kidney organ protective properties both within and outside of a diabetic milieu context [72,73,74] and could offer an opportunity for organ protection in COVID-19. The gene discussed is SLC5A2; the disease is COVID-19.